TP53 and ovarian cancer: Human ascites derived ovarian cancer cells known to be wild-type for TP53 (iOvCa130) and TP53 mutant (iOvCa147) were treated with increasing doses of simvastatin for 24 h and subjected to WST-1 assay to quantify cell viability.